|
|
| Nomenclature |
|
Symbol:
|
Tg(tetO-APPSwInd)107Dbo
|
|
Name:
|
transgene insertion 107, David R Borchelt
|
|
MGI ID: |
MGI:3708462 |
|
Synonyms: |
tet-APPswe/ind line 107 |
|
Transgene:
|
Tg(tetO-APPSwInd)107Dbo
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
(C57BL/6J x C3H/HeJ)F1
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The mouse amyloid beta (A4) precursor protein (APP) sequence was modified to contain a humanized amyloid-beta (Abeta) domain. This mouse/human chimeric APP (mo/huAPP695 or APP695) was mutated to incorporate the Swedish (KM570/571NL) and Indiana (V617F) APP mutations associated with Alzheimer's disease. This APP695swe/ind sequence was placed downstream of the tetracycline-responsive (TRE or tetO) promoter and mouse prion protein exons 1-2. Line 107 was established and most thoroughly studied. (J:109829)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
| References |
|
Original: |
J:109829
Jankowsky JL et al.,
"Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease."
PLoS Med 2005 Dec;2(12):e355
|
|
All: |
3 reference(s)
|
|
Analysis Tools
